FDA rejects Summit and Akeso's ivonescimab for lung cancer

The PD-1/VEGF bispecific antibody improved progression-free survival but showed no statistically significant overall survival benefit in EGFR-mutated non-small cell lung cancer.

By Hana Sorensen, Biotech and trials correspondent
. 2-minute read.
Main entrance of FDA Building 1 with circular driveway
The main entrance of FDA Building 1 on the FDA campus in Silver Spring, Maryland. Photograph: The U.S. Food and Drug Administration/Wikimedia Commons (public domain)

The Food and Drug Administration has rejected ivonescimab for a type of lung cancer, STAT reported Sunday. BioSpace reported Sunday that the drug is a PD-1/VEGF bispecific antibody from Summit Therapeutics and its partner Akeso, and that Summit oversees development outside China. In the Phase 3 HARMONi trial, the drug improved progression-free survival but failed to show a statistically significant overall survival benefit. FDA regulators said in a letter to the companies that the lack of a survival benefit "does not support the positive benefit-risk profile in support of approval."

Summit received a complete response letter for its biologics license application. FDA reviewers wrote that the progression-free survival benefit "in the absence of a statistically significant OS benefit" does not indicate a positive benefit-risk profile. Robert Duggan, Summit's co-CEO, said in a statement that the company was "disappointed for patients and their families awaiting additional treatment options" and believed the global HARMONi study "provided the basis for a treatment option that these patients needed." Had the drug won approval, it would have been the first PD-1/VEGF bispecific antibody cleared in the United States. Akeso has sold ivonescimab in China for this indication since 2024. Summit presented additional data in September showing a slight overall survival benefit in the overall global population, but it was not enough, and the company did not say what it will do next for the EGFR indication. Analysts had been bullish that the drug would be approved, but the agency was not persuaded.

A Tech Times report cited by Clinical Observer on Thursday said Summit's biologics license application seeks regular approval, not accelerated approval, for adults with EGFR-mutated non-small cell lung cancer that had worsened after a third-generation EGFR tyrosine kinase inhibitor. The HARMONi trial enrolled 438 participants with EGFR-mutated non-squamous non-small cell lung cancer that was locally advanced or metastatic and had progressed despite such treatment. Participants were assigned to receive either ivonescimab plus platinum-based chemotherapy or chemotherapy alone. Results published in The Lancet Oncology in September 2026 showed median progression-free survival of 6.8 months for ivonescimab versus 4.4 months for the control arm (hazard ratio 0.52, 95% CI 0.41–0.66; p<0.00001). The primary analysis in April 2025 did not show a statistically significant overall survival difference, with a hazard ratio of 0.79 (p=0.057). Interim analyses in September 2025 and June 2026 yielded hazard ratios of 0.78 and 0.76, respectively, but neither met the prespecified threshold for significance. According to that report, Summit provided the June 2026 survival data to the FDA on July 22, after the agency accepted the application. AstraZeneca said in September that it would invest $2 billion in Summit, securing shared US commercialization rights, though that investment does not settle the survival uncertainty. A study in JAMA in July found that roughly 8 percent of cancer drugs approved based on surrogate endpoints eventually demonstrated an overall survival benefit.

Sources: STAT, BioSpace, Clinical Observer

Hana SorensenBiotech and trials correspondent

Hana Sorensen covers drug developers, clinical trials and their results for Clinical Observer. Hana writes from trial registries, company filings, preprints and published reporting, and links every source.

Corrections. Report an error to corrections@clinicalobserver.com. Read our corrections policy.